By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BioTime, Inc. 

1301 Harbor Bay Parkway

Alameda  California  94502  U.S.A.
Phone: 510-521-3390 Fax: 510-521-3389


Key Statistics

Ownership: Public

Web Site: BioTime
Symbol: BTX

Company News
BioTime (BTX) Co-CEO Adi Mohanty To Participate In Panel Discussion At The Cell & Gene Therapy CEO Forum 9/21/2017 6:39:05 AM
BioTime (BTX) Awarded Grant From The NIH 9/18/2017 6:32:48 AM
Two Key BioTime (BTX) Patents Providing Protection To Opregen Remain Upheld 9/15/2017 6:36:54 AM
BioTime (BTX) Announces $2 Million Grant For Further Development Of OpRegen For Dry-AMD 8/14/2017 6:42:17 AM
BioTime (BTX) Reports Second Quarter Results And Recent Corporate Accomplishments 8/3/2017 6:40:08 AM
BioTime (BTX) Receives DSMB Approval To Start Third Patient Cohort In Clinical Trial For Dry-AMD; Commences Patient Enrollment In The U.S. 7/26/2017 7:16:18 AM
BioTime (BTX) To Announce Second Quarter 2017 Results On August 2, 2017 7/20/2017 9:01:25 AM
Data From BioTime (BTX)’s Phase I/IIa Opregen Trial To Be Presented At The 2017 American Academy of Ophthalmology Annual Meeting 7/19/2017 6:44:07 AM
BioTime (BTX) To Host Key Opinion Leader Event On The Topic Of Dry AMD In New York City 7/18/2017 7:24:57 AM
BioTime (BTX) Subsidiary AgeX Therapeutics, Inc. Appoints Aubrey De Grey, Ph.D. As VP Of New Technology Discovery 7/13/2017 6:28:14 AM